Pfizer rises after FDA approves expanded use of TUKYSA

What happened

Pfizer (PFE) rose 1.8% on October 7, 2026, after the U.S. Food and Drug Administration approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a maintenance treatment for certain HER2-positive metastatic breast cancer, according to Business Wire and Benzinga. The stock opened 0.4% above the previous close and trading volume ran 0.9 times its 20-day average. The move came after company news expanding an approved regimen in metastatic disease, and outpaced the S&P 500, which fell 0.2% that day.

How big was the move

The stock's rise measured 1.5 times a typical daily move for this stock, a large, mostly company-specific move that followed the FDA action. Over the last five sessions the stock fell 1.8% even as the S&P 500 rose 2.0%, and the healthcare sector median fell 0.4% on October 7, making the stock 2.3 percentage points better than the sector median. The company's market value stood at $158.44 billion on the session date.

The technical picture

The stock traded 0.2% above its 20-day moving average and 1.8% above its 50-day moving average while sitting 5.9% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 44 consecutive trading days above the 200-day average. The Relative Strength Index (14 days) was 52, in a neutral range between 30 and 70, and the stock remained 4.1% below the 52-week high. Over the past three months the stock rose 15.5% and over the last year it rose 5.9%, trailing the S&P 500 by 9.8 percentage points.

Fundamentals and valuation

For the four quarters through June 28, 2026, Pfizer reported revenue of $63.70 billion, a decline of 0.2% from a year earlier, and diluted earnings per share of $0.76, which fell 59.9% from a year earlier. Gross margin improved to 71.3% from 67.3% a year earlier while operating margin stood at 25.1% versus 29.6% a year earlier. The balance sheet showed net debt of 4.9 times EBITDA and return on invested capital of 9.3%. Free-cash-flow margin was 17.2% and share count decreased by 0.1% over one year.

On valuation, the stock trades at 37.0 times trailing earnings, higher than 89% of its own readings over the past five years, and at 9.4 times expected forward earnings with a free-cash-flow yield of 6.9%. That gap between a high trailing multiple and a lower forward multiple reflects the recent mix of temporary earnings pressure and stronger cash generation. PromtFinance scores rank the company high on Quality at 87 and Stability at 84, while Growth stood at 11 and Revisions at 44.

Earnings and analyst expectations

Pfizer's last quarterly report, on August 4, 2026, showed earnings per share of $0.77 against $0.68 expected, 12.9% above estimates, marking the company's 14th consecutive quarter beating estimates. The average surprise over the last four reports was 17.7% above estimates and the typical two-day reaction after recent reports was that the stock rose 0.4%. Analysts covering the stock number 39, with a consensus price target of $28.50, 1.8% above the closing price, and a consensus rating of Hold; 38% of ratings were Buy. The next report is scheduled for November 3, 2026.

What to watch

• November 3, 2026: next quarterly report date.
• The FDA-approved label expansion for TUKYSA as maintenance following induction therapy and any follow-up commercial guidance.
• Changes in net debt of 4.9 times EBITDA and any updates to capital allocation or share-count plans.
• Movement versus the 52-week high, currently 4.1% below that high.
• Any additional job actions or plant-level developments following the reported plan to cut about 330 jobs at the Sicily manufacturing site.